2.55
+0.39%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Resources Medical Holdings Company
Its shares trade on HKEX under the ticker 1515.HK. It has been listed since 29 November 2013. In the fiscal year to 31 December 2025, it reported revenue of CN¥10.68bn and net income of CN¥577.5m. At that date it held total assets of CN¥15.04bn and shareholders' equity of CN¥7.63bn.
China Resources Medical Holdings Co., Ltd. operates as an investment holding company. The company is headquartered in Beijing, Beijing. The company went IPO on 2013-11-29. Along with subsidiaries, the Company operates its business through four segments. The GPO Business segment is involved in the sales of pharmaceuticals, medical devices and medical consumables to Jian Gong Hospital, the Internet of things (IOT) Hospitals and external customers. The General Healthcare Services segment provides hospital services provided through Jian Gong Hospital and 999 Medical Clinic (Shenzhen) Co., Ltd. The Hospital Management and Consulting Services segment provides comprehensive management and consulting services to IOT Hospitals and sponsored hospitals and receives an annual fee. The Other Hospital-Derived Services segment provides medical consultation service to third parties.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 29 Nov 2013
- Employees
- 1,178
- Website
- crphoenix.hk ↗
Leadership
Pay as last reported
- Mr. Hai YuExecutive Chairman of the Board, Chief Executive Officer, since 2023
- Ms. Min YangChief Financial Officer, Executive Director, since 2023
- Mr. Du LinVice President, Board Secretary
- Ms. Yanjun FuVice President, since 2017CN¥2.9m
- Mr. Zhou HangVice President
- Mr. Wu XinchunVice President
- Mr. Ming Fai ChungCompany Secretary
- Ms. Lu GeNon-Executive Director
- Mr. Tingmei FuNon-Executive Independent Director
- Ms. Wing Sze LoNon-Executive Independent Director
- Mr. Ting Yuk WuIndependent Non-Executive DirectorCN¥887,000
- Mr. Peng ZhouNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Resources Medical Holdings Company Ltd (CRM) has several strengths that contribute to its success in the medical industry. Firstly, CRM benefits from a strong financial position backed by its affiliation with China Resources Group, one of China's largest state-owned conglomerates. This provides CRM with ample resources and financial stability, allowing for strategic investments and expansions.
- Secondly, CRM operates a diverse portfolio of medical businesses, including hospitals, clinics, pharmaceutical manufacturing, and distribution. This diversification helps CRM mitigate risks and capture opportunities across different segments of the healthcare market.
- Additionally, CRM has established a solid reputation for delivering high-quality medical services and products. This reputation is supported by its experienced management team, renowned medical professionals, advanced technology, and adherence to international healthcare standards.
Weaknesses
- While CRM boasts many strengths, it also faces certain weaknesses that require attention. Firstly, as CRM primarily operates in the Chinese market, its business is subject to the regulations and policies implemented by the Chinese government. This dependence on governmental policies can limit CRM's flexibility and hinder its ability to fully capitalize on international opportunities.
- Furthermore, CRM's extensive business portfolio can also pose challenges in terms of management and resource allocation. Coordinating various medical businesses with distinct operational requirements and regulations can be complex and resource-intensive.
Opportunities
- China's growing middle class and increasing healthcare expenditure present significant opportunities for CRM's long-term growth. The rising affluence of Chinese consumers provides a larger customer base for CRM's medical services and products.
- Moreover, CRM can explore further expansion into international markets, leveraging its expertise, reputation, and financial strength. Expanding its operations beyond the domestic market can help CRM diversify revenue streams and reduce dependency on the Chinese regulatory environment.
Threats
- Despite its strong position in the medical industry, CRM faces certain threats that require careful monitoring. Firstly, the intensifying competition within the healthcare sector in China poses a challenge, as both domestic and foreign players seek to capture market share.
- Additionally, CRM's reliance on technological advancements and innovations in the healthcare industry exposes the company to potential disruptions. Rapid technological changes may require significant investments and adaptations to stay competitive.
- Furthermore, geopolitical uncertainties and trade tensions can impact CRM's international expansion plans and cross-border business collaborations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.